AEE788
AEE788
AEE788 (pronounced: A-E-E-Seven-Eight-Eight) is a novel multi-targeted tyrosine kinase inhibitor that is currently under investigation for its potential use in the treatment of various types of cancer.
Etymology
The term "AEE788" is a proprietary name given by the pharmaceutical company Novartis. The "AEE" part of the name does not have a known etymology, while "788" is a numerical designation.
Definition
AEE788 is a type of drug known as a tyrosine kinase inhibitor. Tyrosine kinases are enzymes that can transfer a phosphate group from ATP to a protein in a cell. By inhibiting these enzymes, AEE788 can prevent the growth and division of cancer cells.
Related Terms
- Tyrosine kinase inhibitor: A type of drug that blocks the action of enzymes known as tyrosine kinases.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Novartis: A Swiss multinational pharmaceutical company based in Basel, Switzerland.
- ATP: Adenosine triphosphate, a complex organic chemical that provides energy to drive many processes in living cells.
Usage
AEE788 is currently being studied in clinical trials for its potential use in the treatment of various types of cancer, including breast cancer, lung cancer, and glioblastoma.
See Also
External links
- Medical encyclopedia article on AEE788
- Wikipedia's article - AEE788
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski